Platelet inhibition is a prerequisite for successful percutaneous coronary interventions (PCI). Aspirin was the first antiplatelet agent with proven benefit in ST-elevation infarction (STEMI) in the era of thrombolysis, significantly lowering death rate and the recurrence of ischaemic events.
Bivalirudin, abciximab and clopidogrel in modern PCI: interpretation and experience from King’s College Hospital
March 2006Br J Cardiol (Acute Interv Cardiol) 2006;13:AIC 5–AIC 8 Leave a commentClick any image to enlarge
